Perkovic, Vlado http://orcid.org/0000-0002-4257-7620
Toto, Robert
Cooper, Mark E.
Mann, Johannes F.E.
Rosenstock, Julio http://orcid.org/0000-0001-8324-3275
McGuire, Darren K. http://orcid.org/0000-0002-6412-7989
Kahn, Steven E.
Marx, Nikolaus http://orcid.org/0000-0001-6141-634X
Alexander, John H.
Zinman, Bernard http://orcid.org/0000-0002-0041-1876
Pfarr, Egon
Schnaidt, Sven
Meinicke, Thomas
von Eynatten, Maximillian
George, Jyothis T.
Johansen, Odd Erik http://orcid.org/0000-0003-2470-0530
Wanner, Christoph http://orcid.org/0000-0001-9507-5301
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy and Safety of Linagliptin in Subjects With Long-standing Type 2 Diabetes Mellitus (>10 Years): Evidence From Pooled Data of Randomized, Double-blind, Placebo-controlled, Phase III Trials
https://doi.org/10.1016/j.clinthera.2014.07.020
Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies
https://doi.org/10.1016/j.clinthera.2014.06.008
Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy
https://doi.org/10.1016/s0140-6736(14)61402-1
Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial (Results)
https://doi.org/10.2337/dc19-0783
Nonglycemic Outcomes of Antidiabetic Medications
https://doi.org/10.2337/cd18-0015
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial (Results)
https://doi.org/10.2337/dc20-0279
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
https://doi.org/10.2337/dc15-2237
DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials
https://doi.org/10.2337/dc20-2018
Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial
https://doi.org/10.2337/dc14-2868
Kidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes
https://doi.org/10.1053/j.ajkd.2015.03.024
An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors
https://doi.org/10.1080/14740338.2019.1626823
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
https://doi.org/10.1186/s12933-018-0682-3
SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management
https://doi.org/10.2337/dc18-0588
Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials
https://doi.org/10.1136/bmjdrc-2014-000020
Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
https://doi.org/10.2337/dc17-0068